Nanobiofar Group, Department of Pharmacy and Pharmaceutical Technology, University of Santiago de Compostela, 15782 Santiago de Compostela, Spain.
Vaccine. 2010 Mar 19;28(14):2607-14. doi: 10.1016/j.vaccine.2010.01.011. Epub 2010 Jan 20.
The design of effective vaccine delivery vehicles is opening up new possibilities for making immunization more equitable, safe and efficient. In this work, we purpose polysaccharidic-based nanoparticles as delivery structures for virus-like particle antigens, using recombinant hepatitis B surface antigen (rHBsAg) as a model. Polysaccharidic-based nanoparticles were prepared using a very mild ionic gelation technique, by cross-linking the polysaccharide chitosan (CS) with a counter ion. The resulting nanoparticles could be easily isolated with a size in the nanometric range (160-200 nm) and positive surface charge (+6 to +10 mV). More importantly, CS-based nanoparticles allowed the efficient association of the antigen (>60%) while maintaining the antigenic epitope intact, as determined by ELISA and Western blot. The entrapped antigen was further released in vitro from the nanoparticles in a sustained manner without compromising its antigenicity. In addition, loaded CS-based nanoparticles were stable, and protected the associated antigen during storage, either as an aqueous suspension under different temperature conditions (+4 degrees C and -20 degrees C), or as a dried form after freeze-drying the nanoparticles. Finally, immunization studies showed the induction of important seroprotection rates after intramuscular administration of the nanoparticles, indicating their adjuvant capacity. In fact, CS-based nanoparticles were able to induce anti-HBsAg IgG levels up to 5500 mIU/ml, values 9-fold the conventional alum-adsorbed vaccine. In conclusion, we report here a polysaccharidic nanocarrier which exhibits a number of in vitro and in vivo features that make it a promising adjuvant for vaccine delivery of subunit antigens.
有效的疫苗输送载体的设计为实现免疫接种更加公平、安全和高效开辟了新的可能性。在这项工作中,我们将多糖纳米颗粒作为病毒样颗粒抗原的输送结构,以重组乙型肝炎表面抗原(rHBsAg)为模型。多糖纳米颗粒是通过使用非常温和的离子凝胶技术制备的,该技术通过将多糖壳聚糖(CS)与反离子交联。所得纳米颗粒可以很容易地通过纳米级(160-200nm)和正表面电荷(+6 至+10mV)的尺寸进行分离。更重要的是,CS 基纳米颗粒允许抗原高效结合(>60%),同时保持抗原表位完整,如通过 ELISA 和 Western blot 确定。包封的抗原可以在体外以持续的方式从纳米颗粒中释放出来,而不会损害其抗原性。此外,负载 CS 基纳米颗粒在储存过程中是稳定的,并保护结合的抗原,无论是在不同温度条件(+4°C 和-20°C)下作为水性悬浮液,还是在纳米颗粒冷冻干燥后作为干燥形式。最后,免疫研究表明,经肌肉内给予纳米颗粒后,可诱导重要的血清保护率,表明其具有佐剂作用。事实上,CS 基纳米颗粒能够诱导高达 5500mIU/ml 的抗-HBsAg IgG 水平,是传统铝吸附疫苗的 9 倍。总之,我们在这里报告了一种多糖纳米载体,它表现出许多体外和体内特征,使其成为亚单位抗原疫苗输送的有前途的佐剂。